期刊文献+

叶酸和聚乙二醇双修饰的壳聚糖纳米粒的制备及其性能表征 被引量:12

Preparation and Characterization of Folic Acid and PEG Conjugated Chitosan Nanoparticles
原文传递
导出
摘要 目的利用离子交联和化学交联相结合的方法制备壳聚糖纳米粒子(NPs),并对NPs分别进行了叶酸(FA)和聚乙二醇(PEG)的修饰。方法通过红外光谱进行结构验证;用扫描电镜和粒度分析仪对粒子的微观形态、粒径、电位等进行了表征;通过与Hela细胞摄取实验对其靶向作用进行验证。结果离子交联和化学交联相结合的方法制备壳聚糖纳米粒子粒径在200 nm左右并且粒径分布窄,修饰后的NPs(FA-NPs、PEG-NPs及FA+PEG-NPs)粒径不受功能基团修饰的影响。激光共聚焦试验证明FA-NPs及FA+PEG-NPs能显著提高细胞对粒子的摄取,而PEG-NPs则明显降低其对粒子的摄取。结论 FA+PEG-NPs有望成为一种新型的药物载体,用于抗癌药物对癌细胞的主动靶向。 OBJECTIVE An ionic gelation combined with chemical crosslinking method was developed to prepare chitosan nanoparticles, followed by conjugation with folate (FA) and polyethylene glycol (PEG). METHODS The structures were verified by infrared spectroscopy. The morphology, diameter and Zeta electric potential of the nanoparticles were assayed by environmental scanning electron microscope and scattering particle analyzer. The specificity of the FA+PEG-NPs targeting cancer cells was demonstrated by human adenocarcinoma Hela cells. RESULTS The chitosan NPs presented a narrow size distribution with an average diameter about 200 nm regardless of the type of functional group. Laser confocal scanning imaging proved that both FA+PEG-NPs and FA-NPs could greatly enhance uptake by Hela cells. However, the PEG-NPs showed contrary results. CONCLUSION FA+PEG-NPs can be applied as a new vehicle to actively deliver anticancer drugs to tumor cells.
出处 《中国现代应用药学》 CAS CSCD 2013年第3期284-289,共6页 Chinese Journal of Modern Applied Pharmacy
基金 厦门市科学技术计划资助项目(3502Z20114007)
关键词 药物释放系统 壳聚糖 叶酸 聚乙二醇 纳米载体 drug release system chitosan folic acid PEG nanocarriers
  • 相关文献

参考文献12

  • 1屠哲玮,陶一飞,董缙,徐云根.细胞毒药物与肿瘤血管生成[J].中国现代应用药学,2011,28(7):618-622. 被引量:7
  • 2LEAMON C P, LOW P S. Folate-mediated targeting: from diagnostics to drug and gene delivery [J]. Drug Discov Today, 2001, 6( I): 44-51.
  • 3吕清,韩旻,李黎明,郑艳榕,李范珠,高建青.双配体修饰的阿霉素脂质体靶向于脑胶质瘤的体外研究[J].中国现代应用药学,2012,29(11):963-970. 被引量:9
  • 4VERONESE F M, PASUT G. PEGylation, successful approach to drug delivery [J]. Drug Discov Today, 2005, 10(21): 1451-1458.
  • 5AGNIHOTRI S A, MALLIKARJUNA N N, AMINABHA VI T M. Recent advances on chitosan-based micro- and nanoparticles in drug delivery [J].J Control Release, 2004, 100(1): 5-28.
  • 6陈娟,胡权,侯振清,张其清.离子诱导结合化学交联法制备壳聚糖纳米粒及其作为药物靶向缓释载体的初步研究[J].中国药学杂志,2010,45(18):1400-1403. 被引量:2
  • 7ZHANG B, LI Y Q, FANG C Y, et al. Receptor-mediated cellular uptake of folate-conjugated fluorescent nanodiamonds: a combined ensemble and single- particle study (J). Small, 2009,5(23): 2716-2721.
  • 8YOUJ, LI X, CUI F D, et al. Folate-conjugated polymer micelles for active targeting to cancer cells: preparation, in vitro evaluation of targeting ability and cytotoxicity [J]. Nanotechnology, 2008,19(4): 1-10.
  • 9MAO H Q, ROY K, TROUNG-LE V L, et al. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency [J].J Control Release, 2001, 70(3): 399-421.
  • 10NAGAMOTO T, HATTORI Y, TAKAYAMA K, et al. Novel chitosan particles and chitosan-coated emulsion inducing immune response via int ranasa1 vaccine delivery [J]. Pharm Res, 2004, 21(4): 671-674.

二级参考文献65

  • 1KHANDARE J, MINKO T. Polymer-drug conjugates: progress in polymeric prodrugs[J]. Prog Polymer Sci, 2006, 31 (4) : 359- 397.
  • 2MAJETI N V, RAVI KUMAR. A review of chitin and chitosan ap- plications [ J ]. React Functi Poly, 2000, 46 ( 1 ) :27.
  • 3SONG Y H, HIRAKU O, YOSHIHARU M, et al. Drug release and antitumor characteristics of N-succinyl-chitosan-mitomycin C as an implant[J].J Controlled Release, 1996,42( 1 ) :93-100.
  • 4KATO Y, ONISHI H, MACHIDA Y. N-succinyl-chitosan as a drug carrier: water-insoluble and water-soluble conjugates [ J]. Biomaterials, 2004, 25 (5): 907-915.
  • 5GUPTA K C, FAWZI H J. Controlled-release formulation for hydroxy urea and rifampicin using polyphosphate-anion-crossinked chitosan microspheres[J]. J Appl Polymer Sci, 2007, 104(3 ) : 1942-1956.
  • 6LOW P S, ANTONY A C. Folate receptor-targeted drugs for cancer and inflammatory diseases - Preface [ J ]. Adv Drug Deliv Rev, 2004, 56 ( 8 ) : 1055-1058.
  • 7FRANCESCO M V, GIANFRANCO P. PEGylation, successful approach to drug delivery. [J]. Drug Discov Today, 2005, 10(21 ): 1541-1548.
  • 8SEMENZA G L. Targeting HIF-I for cancer therapy [J]. Nat Rev Cancer, 2003, 3(10): 721-732.
  • 9RAPISARDA A, ZALEK J, HOLLINGSHEAD M, et al. Schedule-dependent inhibition of hypoxia-inducible factor-lct Protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts [J]. Cancer Res, 2004, 64(19): 6845-6848.
  • 10KANEKO S, ISHIBASHI M, KANEKO M. Vascular endothelial growth factor expression is closely related to irinotecan-mediated inhibition of tumor growth and angiogenesis in neuroblastoma xenografts [J]. Cancer Sci, 2008, 99(6): 1209-1217.

共引文献15

同被引文献140

引证文献12

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部